400 Participants Needed

LLS Program Services for Blood Cancer

Recruiting at 2 trial locations
AK
MP
CA
Overseen ByCarlos A Melara
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Miami
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems likely that you can continue your current treatment since the study focuses on the impact of services and programs, not on changing medical treatments.

Is the LLS Program Services for Blood Cancer treatment generally safe for humans?

The treatment of blood cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia has improved, but safety concerns remain due to side effects like severe cytopenias (low blood cell counts) and unique toxicities from newer drugs. Many drugs for blood cancers have had safety-related changes after approval, including warnings about side effects, so it's important to be cautious and monitor for unrecognized side effects.12345

How does the LLS Program Services for Blood Cancer treatment differ from other treatments for blood cancer?

The LLS Program Services for Blood Cancer treatment is unique because it may involve a comprehensive approach that includes induction, consolidation, and maintenance phases with central nervous system (CNS) prophylaxis, which is a preventive treatment to stop cancer from spreading to the brain and spinal cord. This approach is particularly important for advanced stages of blood cancer, where traditional chemotherapy has shown limited success.678910

What data supports the effectiveness of the LLS Program treatment for blood cancer?

The Leukemia & Lymphoma Society (LLS) enhances patient-centered care by educating patients and healthcare professionals about blood cancers, which can lead to better treatment choices and outcomes. Additionally, patient-reported outcomes (PROs) are used to assess treatment effectiveness and quality of life, providing valuable insights into the patient's perspective on their care.1112131415

Who Is on the Research Team?

Dr. Frank J. Penedo Honored with ISBM ...

Frank Penedo, PhD

Principal Investigator

University of Miami

Are You a Good Fit for This Trial?

This trial is for blood cancer patients currently undergoing treatment who have unmet needs that the Leukemia and Lymphoma Society's (LLS) Program aims to address. Participants must speak English or Spanish, not be using LLS services already, and agree to a 6-month follow-up.

Inclusion Criteria

I need help with medical care, travel, trials, finances, or learning about my disease.
Not be currently participating in any LLS programs or services
I am currently being treated for leukemia, lymphoma, myeloma, MDS, or MPN.
See 1 more

Exclusion Criteria

I do not need help with medical care, travel, trials, finances, or education about my disease.
Are currently participating in any LLS programs or services
I am not willing to participate in follow-up for 6 months.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LLS services and/or standard care for 6 months

6 months
Baseline, 3 month, 6 month visits

Follow-up

Participants are monitored for changes in access to care, quality of life, and financial burden

3 months

What Are the Treatments Tested in This Trial?

Interventions

  • LLS Program
Trial Overview The study evaluates how the LLS Program affects blood cancer patients' access to care, quality of life, and financial burden. It seeks to understand if these services fill gaps in their current care regimen over a six-month period.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: LLS Program and Usual Care GroupExperimental Treatment1 Intervention
Group II: Usual Care GroupActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Miami

Lead Sponsor

Trials
976
Recruited
423,000+

The Leukemia and Lymphoma Society

Collaborator

Trials
87
Recruited
26,200+

Published Research Related to This Trial

The Leukemia & Lymphoma Society (LLS) enhances patient-centered care for blood cancer patients by providing education and resources, empowering patients to make informed treatment choices throughout their care journey.
LLS also supports healthcare professionals through free educational seminars, improving their knowledge of blood cancers and best practices, which strengthens coordination between patients, caregivers, and medical staff.
United States - The Leukemia & Lymphoma Society: Working with patients, carers and hospital professionals to improve awareness, treatment and patient choice.[2015]
Patient-reported outcomes (PROs) are crucial for understanding health outcomes as they provide direct insights into a patient's health status, symptoms, and quality of life, particularly in hematology and oncology settings.
Implementing PROs in clinical practice can enhance patient-physician communication and tailor therapies to individual needs, ultimately improving patient outcomes and the overall quality of care.
Patient-reported outcomes in clinical practice.Dobrozsi, S., Panepinto, J.[2016]
Patient-reported outcomes (PROs) are crucial for understanding treatment benefits from the patient's perspective, especially in hematologic clinical trials, as they provide insights into treatment effectiveness, toxicity, and overall well-being.
The FDA has established guidelines for PRO measures, emphasizing their importance in drug development, particularly when multiple treatment options yield similar survival outcomes, allowing for better clinical decision-making.
Patient-reported outcomes in drug development for hematology.Acquadro, C., Regnault, A.[2021]

Citations

United States - The Leukemia & Lymphoma Society: Working with patients, carers and hospital professionals to improve awareness, treatment and patient choice. [2015]
Patient-reported outcomes in clinical practice. [2016]
Patient-reported outcomes in drug development for hematology. [2021]
The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years. [2018]
Institution of Standardized Consultation Criteria to Increase Early Palliative Care Utilization in Older Patients With Acute Leukemia. [2023]
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. [2023]
Accurate reporting of adverse events in chronic lymphocytic leukemia and non-Hodgkin lymphoma. [2012]
Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies. [2020]
Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery. [2021]
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. [2023]
[Lymphoblastic lymphoma in children. Poor response in advanced disease with chemotherapy for non-Hodgkin's lymphoma]. [2007]
12.Russia (Federation)pubmed.ncbi.nlm.nih.gov
[First experience of using modified program NHL-BFM-90 for the treatment of primary diffuse large-B-cell lymphosarcoma of the bones and soft tissues with poor-prognosis]. [2009]
[Clinical outcome of autologous stem cell transplantation as first-line treatment in 30 patients with high risk lymphoblastic lymphoma]. [2014]
Allogeneic hemopietic stem cell transplants for the treatment of B cell acute lymphocytic leukemia. [2019]
Childhood non-Hodgkin's lymphoma and "leukemia-lymphoma syndrome": long-term results with the modified LSA2-L2 protocol. [2019]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity